Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ChiCTR2000036630Phase 2Not yet recruiting
Phase 2, randomised, open-label trial in intrahepatic cholangiocarcinoma (ICC) comparing Toripalimab + capecitabine with Capecitabine (2 arms). Primary endpoint: recurrence-free survival. Planned start Oct 2020; status: not yet recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on ChiCTR2000036630.